Document:

Exhibit
4.1

 

CONVERTIBLE
BRIDGE LOAN AGREEMENT

 

THIS
CONVERTIBLE BRIDGE LOAN AGREEMENT (this “Agreement”) is entered into as of the 27th day of February
2019 (“Effective Date”), by and between Todos Medical Ltd., an Israeli company (the “Company”),
and the entities set forth on Schedule 1 attached hereto (the “Investors”).

 

WHEREAS,
the Company requires an infusion of funds in order to finance the operations of the Company until the consummation of the Company’s
proposed public financing and uplisting to the NASDAQ Market System; and

 

WHEREAS,
the Investors are willing to make available a convertible bridge loan to the Company in the aggregate amount of around $1,500,000
(the “Aggregate Loan Principal Amount”) and therefore are willing to purchase and the Company is willing to
sell a convertible promissory note and warrant on the terms and conditions set forth in this Agreement;

 

WHEREAS,
the Company and the Investors are executing and delivering this Agreement in reliance upon an exemption from securities registration
pursuant to Section 4(2) and/or Rule 506 of Regulation D (“Regulation D”) as promulgated by the U.S. Securities
and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities
Act”);

 

NOW,
THEREFORE, the parties hereto hereby agree as follows:

 

Certain
Definitions.

 

(a)
“Anti-Bribery Laws” shall mean of any provision of any applicable law or regulation implementing the OECD Convention
on Combating Bribery of Foreign Public Officials in International Business Transactions or any applicable provision of the U.S.
Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the U.K. Bribery Act 2010, or any other similar
law of any other jurisdiction in which the Company operates its business, including, in each case, the rules and regulations thereunder.

 

(b)
“Applicable Laws” shall mean applicable laws, statutes, rules, regulations, orders, executive orders, directives,
policies, guidelines, ordinance or regulation of any governmental entity and codes having the force of law, whether local, national,
or international, as amended from time to time, including without limitation (i) all applicable laws that relate to money laundering,
terrorist financing, financial record keeping and reporting, (ii) all applicable laws that relate to anti-bribery, anti-corruption,
books and records and internal controls, including the Anti-Bribery Laws, (iii) OFAC and any Sanctions Laws or Sanctions Programs,
and (iv) CAATSA and any CAATSA Sanctions Programs, Anti-Money Laundering Laws.

 

(c)
“BHCA” shall mean the Bank Holding Company Act of 1956, as amended.

 

(d)
“CAATSA” shall mean Public Law No. 115-44 The Countering America’s Adversaries Through Sanctions Act.

 

(e)
“CAATSA Sanctions Programs” shall mean a country or territory that is, or whose government is, the subject
of sanctions imposed by CAATSA.

 

     

     

    

 

(f)
“Anti-Money Laundering Laws” shall mean applicable financial recordkeeping and reporting requirements and all
other applicable U.S. and non-U.S. anti-money laundering laws, rules and regulations, including, but not limited to, those of
the Currency and Foreign Transactions Reporting Act of 1970, as amended, the United States Bank Secrecy Act, as amended by the
USA PATRIOT Act of 2001, and the United States Money Laundering Control Act of 1986 (18 U.S.C. §§1956 and 1957), as
amended, as well as the implementing rules and regulations promulgated thereunder, and the applicable money laundering statutes
of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any governmental agency or self-regulatory.

 

(g)
“OFAC” shall mean the U.S. Department of Treasury’s Office of Foreign Asset Control.

 

(h)
“Sanctioned Country” shall mean a country or territory that is the subject or target of a comprehensive embargo
or Sanctions Laws prohibiting trade with the country or territory, including, without limitation, Crimea, Cuba, Iran, North Korea,
Sudan and Syria.

 

(i)
“Sanctions Laws” shall mean any sanctions administered or enforced by OFAC or the U.S. Departments of State
or Commerce and including, without limitation, the designation as a “Specially Designated National” or on the “Sectoral
Sanctions Identifications List”, collectively “Blocked Persons”), the United Nations Security Council (“UNSC”),
the European Union, Her Majesty's Treasury (“HMT”) or any other relevant sanctions authority.

 

(j)
“Sanctions Programs” shall mean any OFAC, HMT or UNSC economic sanction program including, without limitation,
programs related to a Sanctioned Country.

 

(k)
“Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002, as amended.

 

1.
Convertible Bridge Loan.

 

1.1
Loan Principal. Each Investor agrees to lend to the Company the amount set forth opposite its name in Schedule 1
hereto (the “Loan Principal”), subject to the terms and conditions of this Agreement.

 

1.2
Interest. The Loan Principal will bear interest at a flat rate of ten percent (10%) of the Loan Principal (the “Interest”).

 

1.3
OID. The original issue discount for the bridge loan transaction shall be ten percent (10%) (the “OID”).

 

1.4
Closing. The closing of the bridge loan transaction (the “Closing”) will take place three (3) days following
the Effective Date (the “Closing Date”). At the Closing, each Investor will transfer its Loan Principal minus
the OID, (i.e., 90% of the Loan Principal), to the Company, in accordance with the wire transfer instructions provided
in writing by the Company to the Investors. At the Closing, concurrently with the transfer of the Aggregate Loan Principal Amount
minus the OID to the Company, the Company will deliver to each Investor a Convertible Promissory Note substantially in from attached
hereto as Exhibit A (the “Convertible Promissory Note”).

 

1.5
Maturity Date. The Loan Principal plus the Interest shall be due six (6) months following the Closing Date (the “Maturity
Date”).

 

    2

     

    

 

2.
Conversion

 

2.1
Optional Conversion. Without derogating from the provisions of Section 3 below, each Investor shall have at any time after
the Maturity Date (including immediately prior to an Event of Default, as defined below) the option to convert his Loan Principal
plus the Interest into Ordinary Shares of the Company, at a conversion price equal to 70% of the lowest closing bid price of the
Company’s Ordinary Shares in the five (5) days prior to the conversion as quoted by Bloomberg, LP.

 

2.2
Default Conversion. If an Event of Default (as defined in Section 3.2 below) shall have occurred, each Investor shall have
the right to convert his Loan Principal plus the Interest into Ordinary Shares of the Company at a default conversion price equal
to 60% of the lowest closing bid price of the Company’s Ordinary Shares in the fifteen (15) days prior to the conversion
as quoted by Bloomberg, LP.

 

2.3
Share Certificates. The Company shall, promptly upon any conversion of an Investor’s Loan Principal plus the Interest,
issue and deliver to the Investor a certificate representing the number of Ordinary Shares of the Company to which the Investor
shall be entitled upon conversion of the Loan Principal and the Interest (bearing such legends as are required under applicable
law, in the opinion of counsel of the Company).

 

2.4
Irrevocable Transfer Agent Instructions. At the Closing, the Company shall execute and deliver to the Company’s transfer
agent an irrevocable transfer agent instruction in the form attached hereto at Exhibit C.

 

2.5
Conversion Limitation. Each Investor may not convert the Loan Principal and the Interest if the sum of (i) the number of
Ordinary Shares beneficially owned by the Investor and its affiliates on conversion, (ii) any Ordinary Shares issuable in connection
with the unconverted portion of the Loan Principal and the Interest, and (iii) the number of Ordinary Shares issuable upon the
conversion of the Loan Principal and the Interest Note with respect to which the determination of this provision is being made,
would result in beneficial ownership by the Investor and its affiliates of more than 4.99% of the outstanding Ordinary Shares
of the Company. For the purposes of this provision, beneficial ownership shall be determined in accordance with Section 13(d)
of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. The Investor shall have the authority and
obligation to determine whether the restriction contained in this Section 2.5 will limit any conversion hereunder. The Investor
may waive the conversion limitation described in this Section 2.5, in whole or in part, upon and effective after 61 days prior
written notice to the Company to increase its percentage ownership interest to up to 9.99%.

  

    3

     

    

 

3.
Event of Default.

 

3.1
The Loan Principal and the Interest will become, in the Investor’s sole discretion, either immediately repayable or convertible
pursuant to the terms set forth in Section 2.2 above, upon the occurrence of an Event of Default (as defined in Section 3.2 below)
that occurs prior to the repayment of the Loan Principal and the Interest under Section 1 above.

 

3.2
For the purposes of this Agreement, an “Event of Default” shall be deemed to exist upon the occurrence of any
of the following:

 

(a)
Breach of Agreement. The Company breaches any material covenant or other term or condition of this Agreement, the Convertible
Promissory Note or the Warrant and such breach, if subject to cure, continues for a period of twenty (20) business days after
written notice to the Company from the Investor.

 

(b)
Breach of Representations and Warranties. Any material representation or warranty of the Company made herein shall be false
or misleading in any material respect as of the date made and the Closing Date.

 

(c)
Breach of Covenants. Any breach of any covenant to which the Company is obligated hereunder.

 

(d)
Failure to Repay. The Company fails to repay the Loan Principal plus the Interest on the Maturity Date and such failure
continues for a period of ten (10) business days after the Maturity Date.

 

(e)
Bankruptcy. Bankruptcy, insolvency, reorganization, or liquidation proceedings or other proceedings or relief under any
bankruptcy law or any law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted
by or against the Company and if instituted are not dismissed within forty-five (45) days of initiation.

 

(f)
Receiver or Trustee. The Company makes an assignment for the benefit of creditors, or consents to the appointment of a
receiver or trustee for them or for a substantial part of their property or business; or such a receiver or trustee shall otherwise
be appointed.

 

(g)
Judgments. Any money judgment, writ or similar final process shall be entered or filed against the Company or any of its
property or other assets for more than $200,000, and shall remain unvacated, unbonded, uncontested, unsatisfied, or unstayed for
a period of forty-five (45) days.

 

(h)
Stop Trade. A Securities and Exchange Commission or judicial stop trade order with respect to the Company’s Ordinary
Shares is issued that lasts for five (5) or more consecutive trading days.

 

(i)
Financial Statement Restatement. The restatement of any financial statements filed by the Company for any date or period
from two years prior to the Effective Date until the Loan Principal is no longer outstanding, if the result of such restatement
would, by comparison to the original financial statements, materially and adversely affect the Company's financial condition.

 

(j)
The Company fails to (i) file a Registration Statement on Form F-1 in connection with a public offering of its securities, or
(ii) apply for uplisting to the NASDAQ Market System, on or before the Maturity Date.

 

    4

     

    

 

4.
Warrant Coverage

 

4.1
At the Closing, the Company shall deliver to each Investor an Ordinary Share Purchase Warrant (the “Warrant”),
substantially in the form attached hereto as Exhibit B, providing each Investor with a right to purchase such number
of fully-paid and non-assessable restricted Ordinary Shares of the Company (the “Warrant Shares”) in accordance
with the following calculation:

 

(a)
In the event of the consummation of the Company’s proposed public offering and uplisting to the NASDAQ Market System (the
“Uplisting”), the number of Warrant Shares shall be equal in value to twenty-five percent (25%) of such Investor’s
Loan Principal, at an exercise price that is equal to the price of the Company’s shares in the public offering; or

 

(b)
In the event that the Investor converts the Loan Principal into ordinary shares of the Company pursuant to Section 2.1 or Section
2.2 above, then the number of Warrant Shares shall be equal in value to twenty-five percent (25%) of such Investor’s Loan
Principal, at an exercise price that is equal to the closing bid price of the Company’s Ordinary Shares utilized per Section
2.1 or Section 2.2, as applicable, for the conversion of the Loan Principal.

 

4.2
The Warrant shall be issued with the number of Warrant Shares and the exercise price “to be determined”, pending consummation
of the Uplisting or the conversion of the Loan Principal, as applicable. The Investor may exercise the Warrant at any time starting
six (6) months following the Uplisting or the conversion of the Loan Principal, as applicable, and up to three (3) years thereafter.

 

5.
Information on the Company

 

Each
Investor has been furnished with or has had access at the EDGAR Website of the SEC to the Company's Form 20-F filed on May 15,
2018 for the fiscal year ended December 31, 2017 and the financial statements included therein for the year ended December 31,
2017, together with all subsequent filings made with the SEC available at the EDGAR website ("Reports"). In addition,
each Investor may have received in writing from the Company such other information concerning its operations, financial condition
and other matters as such Investor has requested in writing, identified thereon as "Other Written Information" and considered
all factors such Investor deems material in deciding on the advisability of entering into this Agreement.

  

6.
Representations, Warranties and Covenants of the Company

 

The
Company hereby represents, warrants and covenants as follows:

 

6.1
Organization and Qualification. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Israel, and has the requisite corporate power to own its properties and to carry on its business as it
is now being conducted.

 

    5

     

    

 

6.2
Authorization, Enforceability. (i) The Company has the requisite corporate power and authority to enter into this Agreement
and to perform its obligations hereunder in accordance with the terms hereof, (ii) the execution and delivery of this Agreement
by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by the Company’s
Board of Directors and further consent or authorization of the Company by its Board of Directors is not required; and (iii) upon
the execution and delivery of this Agreement by the Company, this Agreement will constitute valid and binding obligations of the
Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement
of creditors’ rights and remedies or by other equitable principles of general application.

 

6.3
Authorized Share Capital. The authorized share capital of the Company consists of 1,000,000,000 ordinary shares, par value
NIS 0.01 per ordinary share, of which 72,399,932 ordinary shares are issued and outstanding.

 

6.4
Issuance of Shares. The Ordinary Shares of the Company that may be issued on conversion of the Loan Principal and on exercise
of the Warrant, when so issued, sold and delivered, will be duly and validly issued, fully paid and nonassessable and will be
issued in reliance upon applicable exemptions from the registration and qualification provisions of all applicable securities
laws of the United States and each state whose securities laws may be applicable thereto. When issued, such Ordinary Shares will
be issued free of any preemptive or similar right and free and clear of any claim, lien, security interest or other encumbrance.

 

6.5
Rule 144 Opinion Letter. The Company, at its cost, shall be responsible for supplying an opinion letter specific to the
fact that the Ordinary Shares of the Company issued pursuant to conversion of the Principal Loan are exempt from registration
requirements pursuant to Rule 144 (so long as the requirements of Rule 144 are satisfied), provided that the Investors will accept
a “blanket” opinion letter that applies to the entirety of the Ordinary Shares that are issued upon conversion of
the Aggregate Principal Loan Amount, so long as such letter is acceptable to Company’s Transfer Agent.

 

6.6
Reports Filed. The Company has filed all reports, schedules, forms, statements and other documents required to be filed
by it with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during
the 2 years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(all of the foregoing filed within the 2 years preceding the date hereof as amended after the date hereof and all exhibits included
therein and financial statements and schedules thereto and documents incorporated by reference therein, being hereinafter referred
to as the “SEC Documents”) on a timely basis or has received a valid extension of such time of filing and has
filed any such SEC Document prior to the expiration of any such extension (including pursuant to SEC from 12b-25). The Company
has delivered to the Investors or its representatives, or made available through the SEC’s website at http://www.sec.gov,
true and complete copies of the SEC Documents. As of their respective dates, the SEC Documents complied in all material respects
with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC
Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements
of the Company and its subsidiaries included in the SEC Documents complied as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have
been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods involved (except
(i) as may be otherwise indicated in such financial statements or (ii) in the case of unaudited interim statements, to the extent
they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject,
in the case of unaudited statements, to normal year-end audit adjustments). No other information provided by or on behalf of the
Company to the Investor which is not included in the SEC Documents contains any untrue statement of a material fact or omits to
state any material fact necessary in order to make the statements therein, in the light of the circumstance under which they are
or were made, not misleading.

 

    6

     

    

 

6.7
10(b)-5. The SEC Documents do not include any untrue statements of material fact, nor do they omit to state any material
fact required to be stated therein necessary to make the statements made, in light of the circumstances under which they were
made, not misleading.

 

6.8
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending against or affecting the Company, the Company’s ordinary
shares, wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect.

 

6.9
CAATSA. To the Company’s knowledge, neither the Company nor any director, officer, agent, employee or affiliate of
the Company, is a Person that is, or is owned or controlled by a Person that has a place of business in, or is operating, organized,
resident or doing business in a country or territory that is, or whose government is, the subject of the CAATSA Sanctions Programs.

 

6.10
Sarbanes-Oxley Act. The Company is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act, that
are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the SEC thereunder that are
applicable to the Company and effective as of the date hereof.

 

6.11
BHCA. The Company is not subject to BHCA and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve). The Company does not own or control, directly or indirectly, 5% or more of the outstanding shares of
any class of voting securities or 25% or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation
by the Federal Reserve. The Company does not exercise a controlling influence over the management or policies of a bank or any
entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

6.12
Compliance with Applicable Laws. The operations of the Company are and have been conducted at all times in compliance Applicable
Laws and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company with respect to Applicable Laws is pending or, to the knowledge of the Company, threatened.

 

    7

     

    

 

6.13
No Conflicts with Sanctions Laws. Neither the Company nor any director, officer, employee, agent, affiliate or other person
associated with or acting on behalf of the Company is directly or indirectly owned or controlled by, a Person that is currently
the subject or the target of any Sanctions Laws or is a Blocked Person; neither the Company, nor any director, officer, employee,
agent, affiliate or other person associated with or acting on behalf of the Company, is located, organized or resident in a country
or territory that is the subject or target of a comprehensive embargo, Sanctions Laws or Sanctions Programs prohibiting trade
with a Sanctioned Country; the Company maintains in effect and enforces policies and procedures designed to ensure compliance
by the Company with applicable Sanctions Laws and Sanctions Programs; neither the Company, nor any director, officer, employee,
agent, affiliate or other person associated with or acting on behalf of the Company, acting in any capacity in connection with
the operations of the Company, conducts any business with or for the benefit of any Blocked Person or engages in making or receiving
any contribution of funds, goods or services to, from or for the benefit of any Blocked Person, or deals in, or otherwise engages
in any transaction relating to, any property or interests in property blocked or subject to blocking pursuant to any applicable
Sanctions Laws or Sanctions Programs; no action of the Company in connection with (i) the execution, delivery and performance
of this Agreement the Convertible Promissory Note and the Warrant (collectively referred to as the “Transaction Documents”),
(ii) the issuance and sale of the Convertible Promissory Note and the Ordinary Shares issuable thereunder and upon exercise of
the Warrant, or (iii) the direct or indirect use of proceeds from issuance of the Convertible Promissory Note or the consummation
of any other transaction contemplated hereby or by the other Transaction Documents or the fulfillment of the terms hereof or thereof,
will result in the proceeds of the transactions contemplated hereby and by the other Transaction Documents being used, or loaned,
contributed or otherwise made available, directly or indirectly, to any subsidiary, joint venture partner or other person or entity,
for the purpose of (i) unlawfully funding or facilitating any activities of or business with any person that, at the time of such
funding or facilitation, is the subject or target of Sanctions Laws or Sanctions Programs, (ii) unlawfully funding or facilitating
any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any Person
(including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions Laws
or Sanctions Programs. For the past 5 years, the Company has not knowingly engaged in and are not now knowingly engaged in any
dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of
Sanctions Laws, Sanctions Programs or with any Sanctioned Country.

 

6.13
No Conflicts with Anti-Bribery Laws. The Company has not made any contribution or other payment to any official of, or
candidate for, any federal, state or foreign office in violation of any law. Neither the Company, nor any director, officer, agent,
employee or other person associated with or acting on behalf of the Company, has (i) used any funds for any unlawful contribution,
gift, entertainment or other unlawful expense relating to political activity, (ii) made any direct or indirect unlawful payment
to any foreign or domestic government official or employee, to any employee or agent of a private entity with which the Company
does or seeks to do business (a “Private Sector Counterparty”) or to foreign or domestic political parties
or campaigns, (iii) violated or is in violation of any provision of any Anti-Bribery Laws, (iv) taken, is currently taking or
will take any action in furtherance of an offer, payment, gift or anything else of value, directly or indirectly, to any person
while knowing that all or some portion of the money or value will be offered, given or promised to anyone to improperly influence
official action, to obtain or retain business or otherwise to secure any improper advantage or (v) otherwise made any offer, bribe,
rebate, payoff, influence payment, unlawful kickback or other unlawful payment; the Company has instituted and has maintained,
and will continue to maintain, policies and procedures reasonably designed to promote and achieve compliance with the laws referred
to in (iii) above and with this representation and warranty; the Company, will not directly or indirectly use the proceeds from
the Convertible Promissory Note or lend, contribute or otherwise make available such proceeds to any subsidiary, affiliate, joint
venture partner or other person or entity for the purpose of financing or facilitating any activity that would violate the laws
and regulations referred to in (iii) above; to the knowledge of the Company, there are, and have been, no allegations, investigations
or inquiries with regard to a potential violation of any Anti-Bribery Laws by the Company, or any of its respective current or
former directors, officers, employees, stockholders, representatives or agents, or other persons acting or purporting to act on
their behalf.

 

    8

     

    

 

6.14
No Disqualification Events. With respect to the Convertible Promissory Note to be offered and sold hereunder in reliance
on Rule 506(b) under the 1933 Act (“Regulation D Securities”), none of the Company, any of its predecessors,
any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder,
any beneficial owner of 20% or more of the Company's outstanding voting equity securities, calculated on the basis of voting power,
nor any promoter (as that term is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time
of sale (each, an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject
to any of the "Bad Actor" disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable
care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent
applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Investor a copy of any disclosures provided
thereunder.

 

6.15
Listing and Maintenance Requirements. The Company’s ordinary shares are registered pursuant to Section 12(b) or 12(g)
or (15(d) of the Exchange Act, and the Company has taken no action designed to terminate, or which to its knowledge is likely
to have the effect of, terminating the registration of the ordinary shares under the Exchange Act nor has the Company received
any notification that the SEC is contemplating terminating such registration. The Company has not, in the 12 months preceding
the date hereof, received notice from the market on which its ordinary shares are listed or quoted to the effect that the Company
is not in compliance with the listing or maintenance requirements of such market. The Company is, and has no reason to believe
that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.

 

6.16
Reporting Status. With a view to making available to the Investors the benefits of Rule 144 or any similar rule or regulation
of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration, and
as a material inducement to the Investors’ purchase of Convertible Promissory Note, the issuance of ordinary shares thereunder
and upon exercise of the Warrant, the Company represents and warrants to the following: (i) the Company is, and has been for a
period of at least 90 days immediately preceding the date hereof, subject to the reporting requirements of section 13 or 15(d)
of the Exchange Act (ii) the Company has filed all required reports under section 13 or 15(d) of the Exchange, as applicable,
during the 12 months preceding the date hereof (or for such shorter period that the Company was required to file such reports),
(iii) the Company is not an issuer defined as a “Shell Company,” and (iv) the Company is not an issuer that has been
at any time previously an issuer defined as a “Shell Company.” For the purposes hereof, the term “Shell Company”
shall mean an issuer that meets the description defined in paragraph (i)(1)(i) of Rule 144.

 

    9

     

    

 

7.
Representations, Warranties, and Covenants of the Investors

 

Each
Investor hereby represents, warrants, acknowledges, understands and agrees (as the case may be) to the following, and acknowledges
that the Company's reliance on exemption from registration pursuant to a registration statement under the Securities Act of 1933,
as amended (the “Securities Act”) is predicated upon the representations of the Investor set forth herein:

 

7.1
Authorization. The Investor has full power and authority to enter into this Agreement, and the Agreement has been duly
executed by the Investor, and such authorization constitutes a valid and legally binding obligation of the Investor, enforceable
in accordance with its terms.

 

7.2
No Registration. The Investor hereby acknowledges that the securities issued pursuant to this Agreement will not be issued
by the Company pursuant to a registration statement under the Securities Act, and therefore the Investor may be required to hold
the securities for an indeterminate period. The securities issued pursuant to this Agreement are issued in reliance upon a specific
exemption from the registration requirement of the Securities Act which depends, in part, upon the accuracy of the representations,
warranties, and agreements of the Investor set forth in this Agreement.

 

7.3
Investor Status. The Investor is: either (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7) or (a)(8) under the Securities Act, or (ii) a non-U.S. Person for which the Company may rely on an exemption from
the registration requirements of United States federal and the state securities laws under Regulation S promulgated under the
Securities Act, or (iii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.

 

7.4
Investment Intent. The Investor is acquiring the securities for the Investor’s own account as principal, not as a
nominee or agent, for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof,
in whole or in part, which resale, distribution or fractionalization would violate the Securities Act. The Investor agrees that
a legend to the foregoing effect may be placed upon any and all certificates issued representing the securities. Further, the
Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations
to such person or to any third person, with respect to the securities, for which the Investor is purchasing. The Investor acknowledges
that he has been afforded the opportunity to ask questions of, and to obtain any information from, the Company and the Board of
Directors as he or she deems necessary to determine the suitability and advisability of, and the merits and risk of, investing
in the Company pursuant hereto.

 

7.5
Risk. The Investor is aware that: (i) investment in the Company involves a high degree of risk, may result in a lack liquidity,
and places substantial restrictions on transferability of interest; and (ii) no Federal or state agency has made any finding or
determination as to the fairness for investment by the public, nor has made any recommendation or endorsement, of the securities.

 

    10

     

    

 

7.6
Financial Ability. The Investor has sufficient financial resources available to support the loss of all or a portion of
the Investor’s investment in the Company, has no need for liquidity in the investment in the Company, and is able to bear
the economic risk of the investment. The Investor is sophisticated and experienced in investment matters, and, as a result, is
in a position to evaluate an investment in the Company.

 

7.7
No Short Sales. Commencing from the Effective Date and continuing until the later of the Maturity Date or the conversion
of the Loan Principal and the Interest, the Investor shall not enter into or effect, or attempt to induce any third party to enter
into or effect, any short sales of the ordinary shares of the Company, or any hedging transaction which establishes a net short
position with respect to the Ordinary Shares of the Company.

 

8.
Covenants of the Company.

 

8.1
Compliance with Applicable Laws. While any Investor owns the Convertible Promissory Note, the Company shall comply with
all Applicable Laws and will not willfully take any action which will cause the Investors to be in violation of any such Applicable
Laws.

 

8.2
Conduct of Business. While the Investor owns the Convertible Promissory Note, the business of the Company shall not be
conducted in violation of Applicable Laws.

 

8.3
While any Investor owns the Convertible Promissory Note, neither the Company, nor any of its, directors, officers, employees,
representatives or agents, shall:

 

(i)
conduct any business or engage in any transaction or dealing with or for the benefit of any Blocked Person, including the making
or receiving of any contribution of funds, goods or services to, from or for the benefit of any Blocked Person;

 

(ii)
deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked or subject to blocking
pursuant to the applicable Sanctions Laws, Sanctions Programs, located in a Sanctioned Country, or CAATSA or CAATSA Sanctions
Programs;

 

(iii)
use any of the proceeds of the transactions contemplated by this Agreement to finance, promote or otherwise support in any manner
any illegal activity, including, without limitation, in contravention of any Anti-Money Laundering Laws, Sanctions Laws, Sanctioned
Program, Anti-Bribery Laws or in any Sanctioned Country.

 

(iv)
violate, attempt to violate, or engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of
evading or avoiding, any of the Anti-Money Laundering Laws, Sanctions Laws, Sanctions Program, Anti-Bribery Laws, CAATSA or CAATSA
Sanctions Programs.

 

8.4
While any Investor owns the Convertible Promissory Note, the Company shall maintain in effect and enforce policies and procedures
designed to ensure compliance by the Company and its directors, officers, employees, agents, representatives and affiliates with
Applicable Laws.

 

    11

     

    

 

8.5
While any Investor owns the Convertible Promissory Note, the Company will promptly notify such Investor in writing if any of the
Company, or any of its directors, officers, employees, representatives or agents, shall become a Blocked Person, or become directly
or indirectly owned or controlled by a Blocked Person.

 

8.6
The Company shall provide such information and documentation it may have as the Investor or any of their affiliates may reasonably
request to satisfy compliance with Applicable Laws.

 

8.7
The covenants set forth above shall be ongoing while any Investor owns the Convertible Promissory. The Company shall promptly
notify such Investor in writing should it become aware during such period (a) of any changes to these covenants, or (b) if it
cannot comply with the covenants set forth herein. The Company shall also promptly notify such Investor in writing during such
period should it become aware of an investigation, litigation or regulatory action relating to an alleged or potential violation
of Applicable Laws.

 

8.8
Reporting Status. With a view to making available to the Investors the benefits of Rule 144 or any similar rule or regulation
promulgated by the United States Securities and Exchange Commission (the “SEC”) that may at any time permit
the Investor to sell securities of the Company to the public without registration, and as a material inducement to the Investors’
purchase of the Convertible Promissory Note and Warrant hereunder, the Company represents, warrants, and covenants to the following:

 

(i)
The Company is subject to the reporting requirements of section 13 or 15(d) of the Exchange Act and has filed all required reports
under section 13 or 15(d) of the Exchange Act during the 12 months prior to the date hereof (or for such shorter period that the
issuer was required to file such reports), other than Form 8-K reports;

 

(ii)
From the date hereof until all the ordinary shares of the Company issued upon conversion of the Convertible Promissory Note or
upon exercise of the Warrant either have been sold by all of the Investors, or may permanently be sold by the Investors without
any restrictions pursuant to Rule 144, (the “Registration Period”) the Company shall file with the SEC in a
timely manner all required reports under section 13 or 15(d) of the Exchange Act and such reports shall conform to the requirement
of the Exchange Act and the SEC for filing thereunder;

 

(iii)
The Company shall furnish to the Investors so long as any Investor owns a Convertible Promissory Note or a Warrant, promptly upon
request, (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, (ii) a copy
of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and
(iii) such other information as may be reasonably requested to permit the Investor to sell such ordinary shares to be issued upon
conversion of the Convertible Promissory Note or exercise of the Warrant pursuant to Rule 144 without registration; and

 

(iv)
During the Registration Period the Company shall not terminate its status as an issuer required to file reports under the Exchange
Act even if the Exchange Act or the rules and regulations thereunder would otherwise permit such termination.

 

    12

     

    

 

8.9
Use of Proceeds. The Company shall not use the proceeds from the issuance of the Convertible Promissory Note hereunder
to fund, either directly or indirectly, any activities or business of or with any Blocked Person, in any Sanctioned Country, (iv)
or in any manner or in a country or territory, that, at the time of such funding, is, or whose government is, the subject of CAATSA
Sanctions Programs or (iv) in any other manner that will result in a violation of Anti-Money Laundering Laws, Sanctions Laws,
Sanctioned Program, Anti-Bribery Laws or CAATSA Sanctions Programs.

 

9.
Piggyback Registration Rights.

 

Until
such time as the ordinary shares of the Company to be issued to the Investor either upon conversion of the Loan Principal or upon
exercise of the Warrant (the “Shares”) are freely transferable pursuant to Rule 144 of the Securities Act, the Company
shall grant the Investor piggyback registration rights with respect to the Shares; excluding, however, the Form F-1 being filed
in connection with the Uplisting and any S-8 Registration Statement of the Company.

 

10.
Conditions to Closing.

 

The
obligations of the Investors hereunder to purchase the Convertible Promissory Note and the Warrant at the Closing is subject to
the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the
Investors’ sole benefit and may be waived by the Investor at any time in its sole discretion:

 

10.1
The Company shall have executed the transaction documents and delivered the same to the Investors;

 

10.2
The Ordinary Shares of the Company shall be authorized for quotation or trading on the market on which they are listed and trading
in the ordinary shares shall not have been suspended for any reason;

 

10.3
The representations and warranties of the Company shall be true and correct in all material respects (except to the extent that
any of such representations and warranties is already qualified as to materiality hereunder, in which case, such representations
and warranties shall be true and correct without further qualification) as of the date when made and as of the Closing Date as
though made at that time (except for representations and warranties that speak as of a specific date) and the Company shall have
performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement
to be performed, satisfied or complied with by the Company at or prior to the Closing Date; and

 

10.4.
The Investors shall have received an opinion of counsel from counsel to the Company in a form satisfactory to the Investors.

 

11.
Limitation of Liability.

 

Neither
party shall be liable hereunder for any indirect, special, or consequential losses or damages of any kind or nature whatsoever,
including but not limited to lost profits, regardless of whether arising from breach of contract, warranty, tort, strict liability
or otherwise, even if advised of the possibility of such loss or damage, or if such loss or damage could have been reasonably
foreseen.

 

    13

     

    

 

12.
Miscellaneous.

 

12.1
Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably be necessary to
carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected thereby.

 

12.2
This Agreement shall be governed by and construed according to the laws of the State of New York, without regard to the conflict
of laws provisions thereof and any dispute, claim or controversy involving this letter agreement, or the circumstances surrounding
the purchase and sale of the Convertible Promissory Note and Warrant described herein shall be settled through binding arbitration
in accordance with the Commercial Rules of the American Arbitration Association, in Manhattan, New York.

 

12.3
Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors,
assigns, heirs, executors, and administrators of the parties hereto.

 

12.4
This Agreement and the Exhibits hereto constitute the full and entire understanding and agreement between the parties with regard
to the subject matters hereof and thereof and supersede any prior agreement, understanding, or contract, written or oral, with
respect to the subject matter hereof and thereof, including any convertible bridge loan agreements signed by the Investors in
the three months prior to the Effective Date.

 

12.5
No delay or omission to exercise any right, power, or remedy accruing to any party upon any breach or default under this Agreement,
shall be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, either under this Agreement
or by law or otherwise afforded to any of the parties, shall be cumulative and not alternative.

 

12.6
If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable under applicable law, then
such provision shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such provision
were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Agreement shall
be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
intention of the excluded provision as determined by such court of competent jurisdiction.

 

12.7
This Agreement may be executed in counterparts.

 

List
of Exhibits:

 

	Schedule
1	Investor
                                         Details – Loan
	Exhibit A:	Convertible Promissory Note
	Exhibit B:	Ordinary Shares Purchase Warrant
	Exhibit C:	Irrevocable Transfer Agent Instruction

 

[Remainder
of Page Left Blank]

 

    14

     

    

 

IN
WITNESS WHEREOF the parties have signed this Convertible Loan Agreement in one or more counterparts as of the date first hereinabove
set forth.

 

The
Company 

 

Todos
Medical Ltd.

 

	/s/
    Herman Weiss	 
	Name:	Herman
    Weiss	 
	Title:	CEO	 
	Date:	February
    27, 2019	 

  

	The
    Investors	 	 	 
	 	 	 	 	 
	YA
    II PN, LTD.	 	DPH
    Investments Ltd.
	 	 	 
	By:	Yorkville
    Advisors Global, LP	 	 	 
	Its:	Investment
    Manager	 	 	 
	 	 	 	/s/
	By:	Yorkville
    Advisors Global II, LLC	 	Name:	 
	Its:	General
    Partner	 	Title:	
	 	 	 	Date:	
	By:	/s/
    David Gonzalez	 	 	 
	Name:	David
    Gonzalez	 	 	 
	Title:	 	 	 	 
	 	 	 	 	 
	Zvi
    David Schnur	 	Gamliel
    Kagan
	 	 	 	 	 
	/s/
    Zvi David Schnur	 	/s/
    Gamliel Kagan
	Name:	Zvi
    David Schnur	 	Name:	Gamliel
    Kagan
	Date:	February
    26, 2019	 	Date:	February
    25, 2019
	 	 	 	 	 
	Joseph
    Schulman	 	Elliot
    Berkovits
	 	 	 	 	 
	/s/
    Joseph     Schulman	 	/s/
    Elliot Berkovits
	Name:	Joseph
    Shulman	 	Name:	Elliot
    Berkovits
	Date:	February
    25, 2019	 	Date:	February
    25, 2019
	 	 	 	 	 
	Boneh
    Chavurot LLC	 	BSD
    Investments Inc.
	 	 	 	 	 
	/s/
    Geoff Rochwarger	 	/s/
	Name:	Geoff
    Rochwarger	 	Name:	 
	Title:	CEO	 	Title:	 
	Date:	February
    27, 2019	 	Date:	February
    25, 2019

 

    15

     

    

 

SCHEDULE
1

 

INVESTOR
DETAILS – LOAN

 

	Investor Name	 	Investor Address	 	Loan Principal	 
	YAII PN, Ltd.	 	1012 Springfield Ave. 
Mountainside, NJ 07092	 	$	500,000	 
	Zvi David Schnur	 	Hativat HaNegev 39, Ashdod, Israel	 	$	30,000	 
	DPH Investments Ltd.	 	Ashdod, Israel	 	$	28,000	 
	Gamliel Kagan	 	11 Rechov HaIris, Bet Shemesh, Israel	 	$	25,000	 
	Joseph Schulman	 	99 South End Drive,	 	$	27,500	 
	Elliot Berkovits	 	Staten Island, NY 10314	 	$	50,000	 
	Boneh Chavurot LLC	 	Bet Shemesh, Israel	 	$	300,000	 
	BSD Investments Inc.	 	Jerusalem, Israel	 	$	390,000	 
	 	 	Aggregate Loan Principal Amount:	 	$	1,350,500	 

  

    16

     

    

 

EXHIBIT
A

 

CONVERTIBLE
PROMISSORY NOTE

 

    17

     

    

 

EXHIBIT
B

 

FORM
OF ORDINARY SHARES PURCHASE WARRANT

 

 

 18Exhibit
4.2

 

EXHIBIT
A

 

FORM
OF CONVERTIBLE PROMISSORY NOTE

 

NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY
ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER
SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

	Loan
    Principal: $_______	Issue
    Date: February __, 2019

 

CONVERTIBLE
PROMISSORY NOTE

 

FOR VALUE RECEIVED, TODOS
MEDICAL LTD., An Israeli company (hereinafter the “Company”), hereby promises to pay __________ (the “Holder”)
or its registered assigns or successors in interest, without demand, a sum equal to ___________ Dollars ($______) (the “Loan
Principal”), plus the Interest (as defined in Section 1 below), on August ___, 2019 (the “Maturity Date”), if
not sooner paid.

 

This Convertible Promissory
Note (the “Note”) has been entered into pursuant to the terms of a Convertible Bridge Loan Agreement between the Company
and the Holder, dated of even date herewith (the “Convertible Loan Agreement”), and shall be governed by the terms
of such Convertible Loan Agreement. Unless otherwise separately defined herein, all capitalized terms used in this Note shall have
the same meaning as is set forth in the Convertible Loan Agreement.

 

The following terms
shall apply to the Note:

 

1. Interest. The Loan Principal
will bear interest at a flat rate of ten percent (10%) of the Loan Principal (the “Interest”).

 

2. Conversion

 

2.1 Optional Conversion.
Without derogating from the provisions of Section 3 below, the Holder shall have at any time after the Maturity Date (including
immediately prior to an Event of Default, as defined below) the option to convert the Loan Principal plus the Interest into Ordinary
Shares of the Company, at a conversion price equal to 70% of the lowest closing bid price of the Company’s Ordinary Shares
in the five (5) days prior to the conversion.

 

2.2 Default Conversion.
If an Event of Default (as defined in Section 3 below) shall have occurred, the Holder shall have the right to convert the Loan
Principal plus the Interest into Ordinary Shares of the Company at a default conversion price equal to 60% of the lowest closing
bid price of the Company’s Ordinary Shares in the fifteen (15) days prior to the conversion.

 

     

     

    

 

2.3 Notice of Conversion.
In the event that the Holder elects to convert any amounts outstanding under this Note into Ordinary Shares, the Holder shall give
notice of such election by delivering an executed and completed notice of conversion (a “Notice of Conversion”) to
the Company via electronic mail, which Notice of Conversion shall detail the amount being converted. The original Note is not required
to be surrendered to the Company until all sums due under the Note have been paid. The date on which a Notice of Conversion is
delivered or telecopied to the Company in accordance with the provisions hereof shall be deemed a “Conversion Date.”
A form of Notice of Conversion to be employed by the Holder is annexed hereto as Exhibit A

 

2.4 Delivery of Certificates.
Within 3 Trading days of the receipt of a Conversion Notice hereunder, the Company at its expense will issue and deliver to the
Holder of this Note a certificate or certificates for the number of shares of the Company issuable upon such conversion, bearing
such legends as are required by applicable state and federal securities laws in the opinion of counsel to the Company.

 

If within 3 Trading Days
after the Company’s receipt by electronic mail of a Conversion Notice the Company shall fail to issue and deliver a certificate
to the Holder for the number of ordinary shares to which the Holder is entitled upon such conversion of any Conversion Amount (a
“Conversion Failure”), and if on or after such Trading Day the Holder purchases (in an open market transaction
or otherwise) ordinary shares to deliver in satisfaction of a sale by the Holder of ordinary shares issuable upon such conversion
that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within 3 Business
Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s
total purchase price (including brokerage commissions and other out of pocket expenses, if any) for the ordinary shares so purchased
(the “Buy-In Price”), at which point the Company’s obligation to deliver such certificate (and to
issue such ordinary shares) shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates
representing such ordinary shares and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over
the product of (A) such number of ordinary shares , times (B) the Closing Price on the Conversion Date.

 

2.5 Mechanics and
Effect of Conversion. No fractional shares shall be issued upon conversion of this Note. In lieu of issuing any fractional
shares upon the conversion of this Note, the Company shall round up any fractional share to the next whole share. Upon conversion
of this Note, the Company shall be forever released from all its obligations and liabilities with respect to the Loan Principal
and accrued interest so converted, which shall be deemed to have been paid in full.

 

2.6 Adjustments to
Conversion Price. The conversion price and number and kind of shares or other securities to be issued upon conversion shall
be subject to adjustment from time to time upon the happening of certain events while this conversion right remains outstanding,
as follows:

 

(a) Merger, Sale
of Assets, etc. If (A) the Company effects any merger or consolidation of the Company with or into another entity, (B) the
Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (C) any tender offer
or exchange offer (whether by the Company or another entity) is completed pursuant to which holders of Ordinary Shares are permitted
to tender or exchange their shares for other securities, cash or property, (D) the Company consummates a stock purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with one or more persons or entities whereby such other persons or entities acquire more than the 50% of the outstanding shares
of Ordinary Shares (not including any shares of Ordinary Shares held by such other persons or entities making or party to, or associated
or affiliated with the other persons or entities making or party to, such stock purchase agreement or other business combination),
(E) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act)
is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50%
of the aggregate Ordinary Shares of the Company, or (F) the Company effects any reclassification of the Ordinary Shares or any
compulsory share exchange pursuant to which the Ordinary Shares is effectively converted into or exchanged for other securities,
cash or property (in any such case, a “Fundamental Transaction”), this Note, as to the unpaid principal portion thereof
and accrued interest thereon, shall thereafter be deemed to evidence the right to convert into such number and kind of shares or
other securities and property as would have been issuable or distributable on account of such Fundamental Transaction, upon or
with respect to the securities subject to the conversion right immediately prior to such Fundamental Transaction. The foregoing
provision shall similarly apply to successive Fundamental Transactions of a similar nature by any such successor or purchaser.

 

    2

     

    

 

(b) Reclassification, etc. If the Company at any time
shall, by reclassification or otherwise, change the Ordinary Shares into the same or a different number of securities of any class
or classes, this Note, as to the unpaid principal portion hereof and accrued interest hereon, shall thereafter be deemed to evidence
the right to convert into an adjusted number of such securities and kind of securities as would have been issuable as the result
of such change with respect to the Ordinary Shares immediately prior to such reclassification or other change.

 

(c) Stock Splits,
Combinations and Dividends. If the Ordinary Shares are subdivided or combined into a greater or smaller number of Ordinary
Shares, or if a dividend is paid on the Ordinary Shares in shares of Ordinary Shares, the Conversion Price shall be proportionately
reduced in case of subdivision of shares or stock dividend or proportionately increased in the case of combination of shares, in
each such case by the ratio which the total number of Ordinary Shares outstanding immediately after such event bears to the total
number of Ordinary Shares outstanding immediately prior to such event.

 

2.7. Reservation. During the period
the conversion right exists, Company will reserve from its authorized and unissued Ordinary Shares not less than one hundred percent
(100%) of the number of shares to provide for the issuance of Ordinary Shares upon the full conversion of this Note. Company represents
that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. Company agrees that its issuance
of this Note shall constitute full authority to its officers, agents, and transfer agents who are charged with the duty of executing
and issuing stock certificates to execute and issue the necessary certificates for Ordinary Shares upon the conversion of this
Note.

 

2.8
Issuance of Replacement Note. Upon any partial conversion of this Note, a replacement Note containing the same date and
provisions of this Note shall, at the written request of the Holder, be issued by the Company to the Holder for the outstanding
Loan Principal of this Note and the Interest which shall not have been converted or paid, provided Holder has surrendered an original
Note to the Company. In the event that the Holder elects not to surrender a Note for reissuance upon partial payment or conversion,
the Holder hereby indemnifies the Company against any and all loss or damage attributable to a third-party claim in an amount in
excess of the actual amount then due under the Note, and the Company is hereby expressly authorized to offset any such amounts
mutually agreed upon by Company and Holder or pursuant to a judgment in Company’s favor against amounts then due under the
Note.

 

3. Event of Default

 

The occurrence of
any of the following events of default (“Event of Default”) shall, at the option of the Holder hereof, make all sums
of principal and interest then remaining unpaid hereon either (i) convertible in Ordinary Shares pursuant to the terms set forth
in Section 2.2 above, or (ii) immediately due and payable, upon demand, without presentment, or grace period, all of which hereby
are expressly waived, except as set forth below:

 

(a) Breach of
Agreement. The Company breaches any material representation or warranty or covenant or other term or condition of the Convertible
Loan Agreement and such breach, if subject to cure, continues for a period of twenty (20) business days after written notice to
the Company from the Holder.

 

    3

     

    

 

(b) Breach of
Representations and Warranties. Any material representation or warranty of the Company made in the Convertible Loan Agreement
shall be false or misleading in any material respect as of the date made and the Closing Date.

 

(c) Failure to
Repay. The Company fails to repay the Loan Principal plus the Interest on the Maturity Date and such failure continues for
a period of ten (10) business days after the Maturity Date.

 

(d) Failure to
Issue Ordinary Shares. The Company fails to issue ordinary shares to the Holder upon conversion of all or a portion of this
Note pursuant to the terms hereunder.

 

(e) Bankruptcy.
Bankruptcy, insolvency, reorganization, or liquidation proceedings or other proceedings or relief under any bankruptcy law or any
law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against the Company
and if instituted are not dismissed within forty-five (45) days of initiation.

 

(f) Receiver or
Trustee. The Company makes an assignment for the benefit of creditors, or consents to the appointment of a receiver or trustee
for them or for a substantial part of their property or business; or such a receiver or trustee shall otherwise be appointed.

 

(g) Judgments.
Any money judgment, writ or similar final process shall be entered or filed against the Company or any of its property or other
assets for more than $200,000, and shall remain unvacated, unbonded, uncontested, unsatisfied, or unstayed for a period of forty-five
(45) days.

 

(h) Stop Trade.
A Securities and Exchange Commission or judicial stop trade order with respect to the Company’s Ordinary Shares is issued
that lasts for five (5) or more consecutive trading days.

 

(i) Financial
Statement Restatement.   The restatement of any financial statements filed by the Company for any date or period
from two years prior to the Effective Date until the Loan Principal is no longer outstanding, if the result of such restatement
would, by comparison to the original financial statements, materially and adversely affect the Company’s financial condition.

 

(j) The Company fails to (i) file a Registration
Statement on Form S-1 in connection with a public offering of its securities, or (ii) apply for uplisting to the NASDAQ Market
System, on or before the Maturity Date.

 

4. Miscellaneous

 

4.1 Failure or
Indulgence Not Waiver. No failure or delay on the part of the Holder hereof in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other right, power or privilege. All rights and remedies existing hereunder are cumulative
to, and not exclusive of, any rights or remedies otherwise available.

 

    4

     

    

 

4.2 Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, facsimile, electronic mail , addressed as set forth below or to such other address as such party shall
have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall
be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile
machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice
is to be received), or the first business day following such delivery (if delivered other than on a business day during normal
business hours where such notice is to be received) (b) receipt, when sent by electronic mail (provided that the electronic mail
transmission is not returned in error or the sender is not otherwise notified of any error in transmission or (c) on the second
business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual
receipt of such mailing, whichever shall first occur. The addresses for such communications shall be: (i) if to the Company to:
Todos Medical Ltd., 1 Hamada, Rehovot, Israel, Attn: Chief Financial Officer, with a copy by telecopier only to: SRK Law Offices,
Oppenheimer 7, Rehovot, Israel, Attn: Steve Kronengold, telecopier: +972-8-936-6000, and (ii) if to the Holder, to the name, address
and telecopy number set forth on the front page of this Note.

 

4.3 Amendment
Provision. The term “Note” and all reference thereto, as used throughout this instrument, shall mean this instrument
as originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

4.4 Assignability.
This Note shall be binding upon the Company and its successors and assigns, and shall inure to the benefit of the Holder and its
successors and assigns.

 

4.5 Cost of Collection.
If default is made in the payment of this Note, Company shall pay the Holder hereof reasonable costs of collection, including reasonable
attorneys’ fees.

 

4.6 Governing
Law. This Note shall be governed by and construed in accordance with the laws of the State of New York, including, but not
limited to, New York statutes of limitations. Any dispute, claim or controversy involving this Note shall be settled through binding
arbitration in accordance with the Commercial Rules of the American Arbitration Association, in Manhattan, New York. Both parties
and the individual signing this Agreement on behalf of the Company agree to submit to the jurisdiction of such courts. The prevailing
party shall be entitled to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision
of this Note is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative
to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such
provision which may prove invalid or unenforceable under any law shall not affect the validity or unenforceability of any other
provision of this Note. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking
other legal action against the Company in any other jurisdiction to collect on the Company’s obligations to Holder, to realize
on any collateral or any other security for such obligations, or to enforce a judgment or other decision in favor of the Holder.
This Note shall be deemed an unconditional obligation of Company for the payment of money and, without limitation to any other
remedies of Holder, may be enforced against Company by summary proceeding pursuant to New York Law or any similar rule or statute
in the jurisdiction where enforcement is sought. For purposes of such rule or statute, any other document or agreement to which
Holder and Company are parties or which Company delivered to Holder, which may be convenient or necessary to determine Holder’s
rights hereunder or Company’s obligations to Holder are deemed a part of this Note, whether or not such other document or
agreement was delivered together herewith or was executed apart from this Note.

 

4.7 Maximum Payments.
Nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other charges in excess of
the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder
exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the
Company to the Holder and thus refunded to the Company.

 

4.8. Construction.
Each party acknowledges that its legal counsel participated in the preparation of this Note and, therefore, stipulates that the
rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation
of this Note to favor any party against the other.

 

4.9 Shareholder
Status. The Holder shall not have rights as a shareholder of the Company with respect to unconverted portions of this Note.
However, the Holder will have the rights of a shareholder of the Company with respect to the Ordinary Shares to be received after
delivery by the Holder of a Conversion Notice to the Company.

 

4.10 Non-Business
Days. Whenever any payment or any action to be made shall be due on a Saturday, Sunday or a public holiday under the laws
of the State of New York, such payment may be due or action shall be required on the next succeeding business day and, for such
payment, such next succeeding day shall be included in the calculation of the amount of accrued interest payable on such date. 

 

    5

     

    

 

IN WITNESS WHEREOF,
Company has caused this Note to be signed in its name by an authorized officer as of the ___ day of February, 2019.

  

	 	TODOS MEDICAL LTD.
	 	 
	 	By:	               
	 	Name:	
	 	Title:	 

 

    6

     

    

 

EXHIBIT A

 

NOTICE OF CONVERSION

 

(To be executed by the Registered Holder
in order to convert the Note)

  

The undersigned hereby
elects to convert $_________ of the principal and $_________ of the interest due on the Note issued by Todos Medical Ltd. (the
“Company”) on _________________ into Ordinary Shares of the Company according to the conditions set forth in such Note,
as of the date written below.

 

	Date of Conversion:	 
	 	 
	 	 
	Conversion Price:	 
	 	 
	 	 
	Shares To Be Delivered:	 
	 	 
	 	 
	Signature:	 
	 	 
	 	 
	Print Name:	 
	 	 
	 	 
	Address:	 
	 	 
	 	 

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]